Startups · 10/27/20261 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Traduzzjoni awtomatika lokali · Il-lingwa oriġinali tas-sors
Sommarju
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Il-lingwa oriġinali tas-sors: PR Newswire UK — News ReleasesAqra l-oriġinal →